H325 - Opioid Epidemic Response Act. (SL 2019-159)

Overview: S.L. 2019-159 removes the registration requirement for buprenorphine prescribers, decriminalizes the use of drug testing equipment, broadens the objectives of syringe exchange programs, and removes the restriction on using State funds to purchase to purchase needles, hypodermic syringes, or other injection supplies.

This act became effective July 22, 2019.